Ertumaxomab

Ertumaxomab (pronunciation: /ɛrˈtjuːmæksɵmæb/) is a tri-functional antibody designed for the treatment of cancer. It is unique in its ability to bind three different types of cells: cancer cells, T cells, and accessory cells.

Etymology

The name "Ertumaxomab" is derived from the Latin "ertus", meaning "true" or "real", and "maximus", meaning "greatest". The "-mab" suffix is common in monoclonal antibodies, indicating the drug's classification.

Mechanism of Action

Ertumaxomab operates by binding to the HER2/neu receptor on cancer cells, a T cell co-receptor CD3, and Fcγ receptor on accessory cells. This tri-functional binding triggers a complex immune response, leading to the destruction of the cancer cell.

Clinical Trials

Ertumaxomab has undergone several clinical trials for various types of cancer, including breast cancer and ovarian cancer. Results have shown promise, particularly in patients with HER2/neu-positive tumors.

Related Terms

• Monoclonal Antibodies
• HER2/neu
• T cells
• Accessory cells
• CD3
• Fcγ receptor
• Clinical trials
• Breast cancer
• Ovarian cancer

See Also

• List of monoclonal antibodies
• Cancer immunotherapy
• HER2/neu positive breast cancer

External links

• Medical encyclopedia article on Ertumaxomab
• Wikipedia's article - Ertumaxomab

This WikiMD article is a stub. You can help make it a full article.

---

Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski